CN109350641A - 一种治疗马鹿呼吸道感染的中西药组合物 - Google Patents
一种治疗马鹿呼吸道感染的中西药组合物 Download PDFInfo
- Publication number
- CN109350641A CN109350641A CN201811360766.5A CN201811360766A CN109350641A CN 109350641 A CN109350641 A CN 109350641A CN 201811360766 A CN201811360766 A CN 201811360766A CN 109350641 A CN109350641 A CN 109350641A
- Authority
- CN
- China
- Prior art keywords
- red deer
- extract
- chinese
- respiratory tract
- tract infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000282985 Cervus Species 0.000 title claims abstract description 26
- 206010057190 Respiratory tract infections Diseases 0.000 title claims abstract description 18
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 36
- AYIRNRDRBQJXIF-NXEZZACHSA-N (-)-Florfenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 AYIRNRDRBQJXIF-NXEZZACHSA-N 0.000 claims abstract description 18
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims abstract description 18
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 claims abstract description 18
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims abstract description 18
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 claims abstract description 18
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims abstract description 18
- 241000050051 Chelone glabra Species 0.000 claims abstract description 18
- 241000334160 Isatis Species 0.000 claims abstract description 18
- KJHOZAZQWVKILO-UHFFFAOYSA-N N-(diaminomethylidene)-4-morpholinecarboximidamide Chemical compound NC(N)=NC(=N)N1CCOCC1 KJHOZAZQWVKILO-UHFFFAOYSA-N 0.000 claims abstract description 18
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims abstract description 18
- 229960000985 ambroxol hydrochloride Drugs 0.000 claims abstract description 18
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims abstract description 18
- 229940074393 chlorogenic acid Drugs 0.000 claims abstract description 18
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims abstract description 18
- 235000001368 chlorogenic acid Nutrition 0.000 claims abstract description 18
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims abstract description 18
- 229960000740 enrofloxacin Drugs 0.000 claims abstract description 18
- 229960003760 florfenicol Drugs 0.000 claims abstract description 18
- 239000001530 fumaric acid Substances 0.000 claims abstract description 18
- 229960005389 moroxydine Drugs 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 229950003874 sulfamonomethoxine Drugs 0.000 claims abstract description 18
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 18
- UURAUHCOJAIIRQ-QGLSALSOSA-N tiamulin Chemical compound CCN(CC)CCSCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 UURAUHCOJAIIRQ-QGLSALSOSA-N 0.000 claims abstract description 7
- 229960004885 tiamulin Drugs 0.000 claims abstract description 7
- VRYALKFFQXWPIH-RANCGNPWSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxy-2-tritiohexanal Chemical compound O=CC([3H])[C@@H](O)[C@H](O)[C@H](O)CO VRYALKFFQXWPIH-RANCGNPWSA-N 0.000 claims abstract description 3
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 claims description 15
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 15
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 claims description 15
- 241000894006 Bacteria Species 0.000 claims description 2
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 4
- 206010066901 Treatment failure Diseases 0.000 abstract description 3
- 244000052769 pathogen Species 0.000 abstract description 3
- 230000001717 pathogenic effect Effects 0.000 abstract description 3
- 208000023504 respiratory system disease Diseases 0.000 abstract description 3
- 206010059866 Drug resistance Diseases 0.000 abstract description 2
- 230000002155 anti-virotic effect Effects 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 241000974009 Cervus canadensis Species 0.000 description 2
- 210000003056 antler Anatomy 0.000 description 2
- 239000005321 cobalt glass Substances 0.000 description 2
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000168096 Glareolidae Species 0.000 description 1
- 241000254223 Syntexis Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
- A61K36/855—Clerodendrum, e.g. glorybower
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种治疗马鹿呼吸道感染的中西药组合物，由以下重量份的原料构成：氟苯尼考150～200g、恩诺沙星50～80g、磺胺间甲氧嘧啶40～60g、盐酸氨溴索15～20g、延胡索酸泰妙菌素20～50g、2‑脱氧‑D‑葡萄糖10～20g、吗啉胍5～10g、金银花提取物绿原酸10～20g、板蓝根提取物6～18g、大青叶提取物5～10g、黄芩提取物10～20g。本发明可避免一些病原菌对一种药物产生耐药性而出现治疗失败的情况，减少病原的耐药几率，使抗病原微生物范围更广，抗菌作用更强，可有效治疗马鹿呼吸道疾病，且可提高病马鹿的抗病毒能力。
Description
技术领域
本发明涉及畜牧领域，具体涉及一种治疗马鹿呼吸道感染的中西药组合物。
背景技术
马鹿是仅次于驼鹿的大型鹿类，共有10个亚种，因为体形似骏马而得名，身体呈深褐色，背部及两侧有一些白色斑点。雄性有角，一般分为6叉，最多8个叉，茸角的第二叉紧靠于眉叉。夏毛较短，没有绒毛，一般为赤褐色，背面较深，腹面较浅，故有“赤鹿”之称。
在马鹿养殖的过程中，马鹿呼吸道感染是一种常见的疾病，主要由由于受寒感冒，受物理化学因素的刺激，机体抵抗力降低，受条件性病原菌的侵害等因素导致的，其主要临床表现为咳嗽、气喘，营养不良、消瘦、精神沉郁,腹式呼吸，病程较长，进而对马鹿生长造成严重的影响。
目前，由于病原复杂，现阶段养殖者还无法用实验室手段通过细菌培养、微生物分离等手段来判定病原种类，治疗失败会导致病情恶化，给养殖者造成很大的经济损失。
发明内容
为解决上述问题，本发明提供了一种治疗马鹿呼吸道感染的中西药组合物，抗菌谱广，抗菌效力强，可有效治疗马鹿呼吸道疾病。
为实现上述目的，本发明采取的技术方案为：
一种治疗马鹿呼吸道感染的中西药组合物，由以下重量份的原料构成：
氟苯尼考150～200g、恩诺沙星50～80g、磺胺间甲氧嘧啶40～60g、盐酸氨溴索15～20g、延胡索酸泰妙菌素20～50g、2-脱氧-D-葡萄糖10～20g、吗啉胍5～10g、金银花提取物绿原酸10～20g、板蓝根提取物6～18g、大青叶提取物5～10g、黄芩提取物10～20g。
优选地，由以下重量份的原料构成：
氟苯尼考150g、恩诺沙星50g、磺胺间甲氧嘧啶40g、盐酸氨溴索15g、延胡索酸泰妙菌素20g、2-脱氧-D-葡萄糖10g、吗啉胍5g、金银花提取物绿原酸10g、板蓝根提取物6g、大青叶提取物5g、黄芩提取物10g。
优选地，由以下重量份的原料构成：
氟苯尼考200g、恩诺沙星80g、磺胺间甲氧嘧啶60g、盐酸氨溴索20g、延胡索酸泰妙菌素50g、2-脱氧-D-葡萄糖20g、吗啉胍10g、金银花提取物绿原酸20g、板蓝根提取物18g、大青叶提取物10g、黄芩提取物20g。
优选地，由以下重量份的原料构成：
氟苯尼考175g、恩诺沙星65g、磺胺间甲氧嘧啶50g、盐酸氨溴索17.5g、延胡索酸泰妙菌素35g、2-脱氧-D-葡萄糖15g、吗啉胍7.5g、金银花提取物绿原酸15g、板蓝根提取物12g、大青叶提取物7.5g、黄芩提取物15g。
优选地，由以下重量份的原料构成：
氟苯尼考175g、恩诺沙星65g、磺胺间甲氧嘧啶50g、盐酸氨溴索17g、延胡索酸泰妙菌素35g、2-脱氧-D-葡萄糖15g、吗啉胍7g、金银花提取物绿原酸15g、板蓝根提取物12g、大青叶提取物7g、黄芩提取物15g。
优选地，由以下重量份的原料构成：
氟苯尼考175g、恩诺沙星65g、磺胺间甲氧嘧啶50g、盐酸氨溴索18g、延胡索酸泰妙菌素35g、2-脱氧-D-葡萄糖15g、吗啉胍8g、金银花提取物绿原酸15g、板蓝根提取物12g、大青叶提取物8g、黄芩提取物15g。
本发明可避免一些病原菌对一种药物产生耐药性而出现治疗失败的情况，减少病原的耐药几率，使抗病原微生物范围更广，抗菌作用更强，可有效治疗马鹿呼吸道疾病，且可提高病马鹿的抗病毒能力。
具体实施方式
下面结合具体实施例对本发明进行详细说明。以下实施例将有助于本领域的技术人员进一步理解本发明，但不以任何形式限制本发明。应当指出的是，对本领域的普通技术人员来说，在不脱离本发明构思的前提下，还可以做出若干变形和改进。这些都属于本发明的保护范围。
实施例1
一种治疗马鹿呼吸道感染的中西药组合物，由以下重量份的原料构成：
氟苯尼考150g、恩诺沙星50g、磺胺间甲氧嘧啶40g、盐酸氨溴索15g、延胡索酸泰妙菌素20g、2-脱氧-D-葡萄糖10g、吗啉胍5g、金银花提取物绿原酸10g、板蓝根提取物6g、大青叶提取物5g、黄芩提取物10g。
实施例2
一种治疗马鹿呼吸道感染的中西药组合物，由以下重量份的原料构成：
氟苯尼考200g、恩诺沙星80g、磺胺间甲氧嘧啶60g、盐酸氨溴索20g、延胡索酸泰妙菌素50g、2-脱氧-D-葡萄糖20g、吗啉胍10g、金银花提取物绿原酸20g、板蓝根提取物18g、大青叶提取物10g、黄芩提取物20g。
实施例3
一种治疗马鹿呼吸道感染的中西药组合物，由以下重量份的原料构成：
氟苯尼考175g、恩诺沙星65g、磺胺间甲氧嘧啶50g、盐酸氨溴索17.5g、延胡索酸泰妙菌素35g、2-脱氧-D-葡萄糖15g、吗啉胍7.5g、金银花提取物绿原酸15g、板蓝根提取物12g、大青叶提取物7.5g、黄芩提取物15g。
实施例4
一种治疗马鹿呼吸道感染的中西药组合物，由以下重量份的原料构成：
氟苯尼考175g、恩诺沙星65g、磺胺间甲氧嘧啶50g、盐酸氨溴索17g、延胡索酸泰妙菌素35g、2-脱氧-D-葡萄糖15g、吗啉胍7g、金银花提取物绿原酸15g、板蓝根提取物12g、大青叶提取物7g、黄芩提取物15g。
实施例5
一种治疗马鹿呼吸道感染的中西药组合物，由以下重量份的原料构成：
氟苯尼考175g、恩诺沙星65g、磺胺间甲氧嘧啶50g、盐酸氨溴索18g、延胡索酸泰妙菌素35g、2-脱氧-D-葡萄糖15g、吗啉胍8g、金银花提取物绿原酸15g、板蓝根提取物12g、大青叶提取物8g、黄芩提取物15g。。
以上对本发明的具体实施例进行了描述。需要理解的是，本发明并不局限于上述特定实施方式，本领域技术人员可以在权利要求的范围内做出各种变化或修改，这并不影响本发明的实质内容。在不冲突的情况下，本申请的实施例和实施例中的特征可以任意相互组合。
Claims (6)
1.一种治疗马鹿呼吸道感染的中西药组合物，其特征在于：由以下重量份的原料构成：
氟苯尼考150～200g、恩诺沙星50～80g、磺胺间甲氧嘧啶40～60g、盐酸氨溴索15～20g、延胡索酸泰妙菌素20～50g、2-脱氧-D-葡萄糖10～20g、吗啉胍5～10g、金银花提取物绿原酸10～20g、板蓝根提取物6～18g、大青叶提取物5～10g、黄芩提取物10～20g。
2.如权利要求1所述的一种治疗马鹿呼吸道感染的中西药组合物，其特征在于：由以下重量份的原料构成：
氟苯尼考150g、恩诺沙星50g、磺胺间甲氧嘧啶40g、盐酸氨溴索15g、延胡索酸泰妙菌素20g、2-脱氧-D-葡萄糖10g、吗啉胍5g、金银花提取物绿原酸10g、板蓝根提取物6g、大青叶提取物5g、黄芩提取物10g。
3.如权利要求1所述的一种治疗马鹿呼吸道感染的中西药组合物，其特征在于：由以下重量份的原料构成：
氟苯尼考200g、恩诺沙星80g、磺胺间甲氧嘧啶60g、盐酸氨溴索20g、延胡索酸泰妙菌素50g、2-脱氧-D-葡萄糖20g、吗啉胍10g、金银花提取物绿原酸20g、板蓝根提取物18g、大青叶提取物10g、黄芩提取物20g。
4.如权利要求1所述的一种治疗马鹿呼吸道感染的中西药组合物，其特征在于：由以下重量份的原料构成：
氟苯尼考175g、恩诺沙星65g、磺胺间甲氧嘧啶50g、盐酸氨溴索17.5g、延胡索酸泰妙菌素35g、2-脱氧-D-葡萄糖15g、吗啉胍7.5g、金银花提取物绿原酸15g、板蓝根提取物12g、大青叶提取物7.5g、黄芩提取物15g。
5.如权利要求1所述的一种治疗马鹿呼吸道感染的中西药组合物，其特征在于：由以下重量份的原料构成：
氟苯尼考175g、恩诺沙星65g、磺胺间甲氧嘧啶50g、盐酸氨溴索17g、延胡索酸泰妙菌素35g、2-脱氧-D-葡萄糖15g、吗啉胍7g、金银花提取物绿原酸15g、板蓝根提取物12g、大青叶提取物7g、黄芩提取物15g。
6.如权利要求1所述的一种治疗马鹿呼吸道感染的中西药组合物，其特征在于：由以下重量份的原料构成：
氟苯尼考175g、恩诺沙星65g、磺胺间甲氧嘧啶50g、盐酸氨溴索18g、延胡索酸泰妙菌素35g、2-脱氧-D-葡萄糖15g、吗啉胍8g、金银花提取物绿原酸15g、板蓝根提取物12g、大青叶提取物8g、黄芩提取物15g。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811360766.5A CN109350641A (zh) | 2018-11-15 | 2018-11-15 | 一种治疗马鹿呼吸道感染的中西药组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811360766.5A CN109350641A (zh) | 2018-11-15 | 2018-11-15 | 一种治疗马鹿呼吸道感染的中西药组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109350641A true CN109350641A (zh) | 2019-02-19 |
Family
ID=65345283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811360766.5A Pending CN109350641A (zh) | 2018-11-15 | 2018-11-15 | 一种治疗马鹿呼吸道感染的中西药组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109350641A (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101439090A (zh) * | 2007-11-20 | 2009-05-27 | 北京生泰尔生物科技有限公司 | 银黄制剂及其用途 |
| CN101584747A (zh) * | 2009-06-29 | 2009-11-25 | 北京大北农科技集团股份有限公司 | 一种抗菌抗病毒兽用中药组合物 |
| CN103860646A (zh) * | 2014-02-27 | 2014-06-18 | 四川劲丰生物技术有限公司 | 动物病毒性疾病继发混合感染的联抗注射液 |
| CN104706825A (zh) * | 2013-12-11 | 2015-06-17 | 天津嘉创生物科技有限公司 | 具有抗病毒功能的中药口服液及其制备方法 |
| CN108653205A (zh) * | 2018-07-26 | 2018-10-16 | 日照市牧邦畜牧科技有限公司 | 一种稳定长效复方替米考星溶液及其制备工艺 |
-
2018
- 2018-11-15 CN CN201811360766.5A patent/CN109350641A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101439090A (zh) * | 2007-11-20 | 2009-05-27 | 北京生泰尔生物科技有限公司 | 银黄制剂及其用途 |
| CN101584747A (zh) * | 2009-06-29 | 2009-11-25 | 北京大北农科技集团股份有限公司 | 一种抗菌抗病毒兽用中药组合物 |
| CN104706825A (zh) * | 2013-12-11 | 2015-06-17 | 天津嘉创生物科技有限公司 | 具有抗病毒功能的中药口服液及其制备方法 |
| CN103860646A (zh) * | 2014-02-27 | 2014-06-18 | 四川劲丰生物技术有限公司 | 动物病毒性疾病继发混合感染的联抗注射液 |
| CN108653205A (zh) * | 2018-07-26 | 2018-10-16 | 日照市牧邦畜牧科技有限公司 | 一种稳定长效复方替米考星溶液及其制备工艺 |
Non-Patent Citations (3)
| Title |
|---|
| Y.BECKER: "《抗病毒药物 作用方式和人类病毒感染的化学治疗》", 31 January 1980, 人民卫生出版社 * |
| 汪明: "《兽医学概论》", 28 February 2011, 中国农业大学出版社 * |
| 白华: "《兽药质量安全知识问答》", 30 June 2012, 中国计量出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103918926B (zh) | 一种鸡饲料中药添加剂 | |
| CN101946990A (zh) | 防治甲型h1n1流感的纳米银硒负离子抗菌口罩 | |
| CN104988079B (zh) | 一种哈茨木霉jsnl1404及其应用 | |
| CN205163904U (zh) | 预防儿童腹泻的保健腹带 | |
| CN106822092A (zh) | 一种抑制嗜水气单胞菌感染的药物组合物 | |
| CN104263673B (zh) | 一种枯草芽孢杆菌b51及其应用 | |
| CN109350641A (zh) | 一种治疗马鹿呼吸道感染的中西药组合物 | |
| CN103947685B (zh) | 一种用于手术室杀菌的药物组合物 | |
| CN108522851A (zh) | 杜仲叶提取物及其在制备用于提高肉兔生长性能的饲料添加剂中的应用 | |
| CN107823326A (zh) | 一种鱼类病原菌抑制剂 | |
| CN106729044A (zh) | 一种防治鱼类孢子虫病的组合物 | |
| CN107779440A (zh) | 一种葡萄球菌噬菌体及其在葡萄球菌感染中的应用 | |
| CN101357123A (zh) | 用于动、植物抗病毒、抗病菌的新方法及其产品 | |
| CN102018703B (zh) | 含有薁磺酸钠的妇科专用冲洗剂 | |
| CN201668890U (zh) | 杀菌抗病毒型口罩 | |
| CN106421505A (zh) | 一种防治甲鱼白底板病的组合物 | |
| CN106421206A (zh) | 一种防治甲鱼腐皮病的组合物 | |
| CN108524725A (zh) | 一种用于口服的二氧化氯溶液 | |
| CN107823325A (zh) | 鱼类病菌抑制剂 | |
| CN101966201A (zh) | 复方烟酸诺氟沙星可溶性粉及其制备方法 | |
| CN104686596A (zh) | 一种空气消毒剂 | |
| CN108748493A (zh) | 一种杜仲条和柳条合编的方法 | |
| CN103961419A (zh) | 一种防治鸡球虫病的中药微生态制剂及制备方法 | |
| CN202588272U (zh) | 一种内裤 | |
| CN106860690A (zh) | 一种防治甲鱼烂嘴病的组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190219 |